# Gujarat Themis Biosyn shares are likely to remain in focus on May 25.

*biotech, business · news · 2026-05-25 · Moneycontrol*

## Key points

- Gujarat Themis Biosyn will acquire 100% equity in MicroBiopharm Japan Co., Ltd.
- The acquisition price is JPY 21.5 billion (about ₹1,300 crore), financed by debt and equity.
- The deal is set to close in Q2FY27, pending regulatory approvals and closing conditions.
- Acquisition will be conducted through a newly formed Special Purpose Vehicle in Japan.

Gujarat Themis Biosyn shares are likely to remain in focus on May 25 after the company announced the acquisition of 100% equity stake in MicroBiopharm Japan Co., Ltd., a Japan-based company with more than six decades of expertise in fermentation, microbial-based research, development, and manufacturing of pharmaceuticals and specialty chemicals. The company has signed a definitive agreement to acquire the entire shareholding of MicroBiopharm Japan from funds managed or advised by T Capital Partners Co., Ltd.. The acquisition will be carried out through a wholly owned Special Purpose Vehicle (SPV) to be incorporated in Japan. According to the company, the transaction is expected to be completed during Q2FY27, subject to customary regulatory approvals and closing conditions. The total acquisition cost stands at JPY 21.5 billion (approximately ₹1,300 crore) and will be financed through an optimal combination of debt and equity. Catch all the market action on our live blog Meanwhile, the board of directors of Gujarat Themis Biosyn is scheduled to meet on May 25, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The board will also consider recommending a dividend on the company’s equity shares for FY26, if any. In the previous trading session, the share closed at Rs 368.85, up Rs 11.75, or 3.29 percent. The share touched a 52-week high of Rs 479.45 and a 52-week low of Rs 225.75 on 27 October, 2025 and 30 March, 2026, respectively. Currently, the stock is trading 23.07 percent below its 52-week high and 63.39 percent above its 52-week low. The market capitalisation of the company stands at Rs 4,019.18 crore.

**Companies:** Gujarat Themis Biosyn
**Countries:** Japan, India

[Read the full story on Moneycontrol](https://www.moneycontrol.com/news/business/stocks/gujarat-themis-biosyn-in-focus-after-rs-1-300-crore-acquisition-deal-for-japanese-firm-13929171.html)

---

Canonical: https://newsio.io/n/b1773b07-0a3f-4dcd-a8a9-b19bc84da3ce/gujarat-themis-biosyn-shares-are-likely-to-remain-in-focus-on-may-25-the-company
Summarized by Newsio from Moneycontrol. https://newsio.io/how-it-works